Publication | Open Access

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

ThrombopoiesisThrombosisAggregate FormationBlood PlateletMedicineImmunologyHematologyBlood CellHemostasisPlatelet AntagonistPharmacologyCell BiologyCell SignalingPlatelet Activation